In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Castanheira, Mariana ^a   Davis, Andrew P ^a   Mendes, Rodrigo E ^a   Serio, Alisa W ^b   Krause, Kevin M ^b   Flamm, Robert K ^a  

^a JMI LABORATORIES   (United States)

^b Achaogen   (United States)

Author keywords

Aminoglycosides; Carbapenem resistant Enterobacteriaceae; Plazomicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEMASE; CEFTAZIDIME; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; TIGECYCLINE; TOBRAMYCIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; SISOMICIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; CITROBACTER KOSERI; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION; GENETICS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PLASMID;

ACINETOBACTER; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; GENE EXPRESSION; GENTAMICINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PLASMIDS; PSEUDOMONAS AERUGINOSA; SISOMICIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TOBRAMYCIN; UNITED STATES;

EID: 85052022786     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00313-18     Document Type: Article

References (18)

1. Pogue JM, Kaye KS, Cohen DA, Marchaim D. 2015. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect 21:302–312. https://doi.org/10.1016/j.cmi.2014.12.025.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. https://doi.org/10.1086/595011.
3. Bassetti M, Merelli M, Temperoni C, Astilean A. 2013. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22. https://doi.org/10.1186/1476-0711-12-22.
4. Savage RD, Fowler RA, Rishu AH, Bagshaw SM, Cook D, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall J, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Daneman N. 2016. The effect of inadequate initial empiric antimicrobial treatment on mortality in critically ill patients with bloodstream infections: a multi-centre retrospective cohort study. PLoS One 11:e0154944. https://doi.org/10.1371/journal.pone.0154944.
5. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. 2003. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 9:412–418. https://doi.org/10.1046/j.1469-0691.2003.00656.x.
6. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13:151–171. https://doi.org/10.1016/j.drup.2010.08.003.
7. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727–737.
8. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54:4636 – 4642. https://doi.org/10.1128/AAC.00572-10.
9. Cox G, Ejim L, Stogios PJ, Koteva K, Borderleau E, Evdokimova E, Sieron AO, Serio AW, Krause KM, Wright GD. 2018. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis 4:980–987. https://doi.org/10.1021/acsinfecdis.8b00001.
10. Karaiskos I, Souli M, Giamarellou H. 2015. Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Invest Drugs 24:1501–1511. https://doi.org/10.1517/13543784.2015.1095180.
11. Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2012. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 10: 459–473. https://doi.org/10.1586/eri.12.25.
12. Abdelraouf K, Kim A, Krause KM, Nicolau DP. 2017. Assessment of the in vivo of plazomicin alone or in combination with meropenem or tigecycline against Enterobacteriaceae isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model, poster 1506. Abstr IDWeek 2017, 4 to 8 October 2017, San Diego, CA.
13. CLSI. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI, Wayne, PA.
14. CLSI. 2017. M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. CLSI, Wayne, PA.
15. EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January 2017. http://www.eucast.org/clinical_breakpoints/. Accessed January 2017.
16. U.S. Food and Drug Administration. 2017. Tigecycline–injection products. FDA-identified interpretive criteria. U.S. Food and Drug Administration, Silver Spring, MD. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm587585.htm. Accessed June 2018.
17. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 66:1409–1411. https://doi.org/10.1093/jac/dkr081.
18. Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70:119–123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002.